Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
While the stage of a prostate cancer can help give an idea of how serious the cancer is likely to be, doctors also use other ways to tell how likely it is that a prostate cancer will grow and spread, which might also help determine a man’s best treatment options.
For cancers that have not spread (stage I to III cancers), many doctors now use information about the cancer (such as the T category, initial PSA level, grade group, and prostate biopsy results) to divide them into risk groups. These risk groups can then be used to help determine treatment options.
These prostate cancers are small, not felt on exam, can only be found in a small area of the prostate, and have not grown outside the prostate (cT1c). They have a Grade Group of 1 (Gleason score of 6 or less) and low PSA levels (less than 10) and few other classification criteria. They usually grow very slowly and are unlikely to ever cause any symptoms or other health problems.
Prostate cancers in this group have not yet grown outside of the prostate, have a Grade Group of 1 (Gleason score of 6 or less) and low PSA levels (less than 10), but are slightly larger (cT1 to cT2a), than very-low-risk cancers.
This group of prostate cancers can be felt on exam or can be seen on an imaging test. The cancer might be found in more than half of one side of the prostate (cT2b) or in both sides of the prostate [cT2c], and/or have a Grade Group of 2 or 3 (Gleason score of 7) and/or a PSA level between 10 and 20 ng/ml. Additional classifications split the intermediate-risk group into favorable and unfavorable categories.
Prostate cancers in this group have grown outside the prostate (cT3a) or have a Grade Group of 4 or 5 (Gleason score 8 to 10) or have a PSA level of more than 20.
These prostate cancers have a very high risk for the tumor growing, coming back, or spreading to the nearby lymph nodes. They have one or more of the following traits:
The risk group can help determine if any further tests should be done, as well as help guide initial treatment options. Cancers in lower risk groups have a smaller chance of growing and spreading compared to those in higher risk groups.
If you have prostate cancer that has not spread to nearby lymph nodes or to other parts of the body, you might want to ask your doctor what risk group your cancer falls into to understand your treatment choices.
In addition to the risk groups above, some doctors are now using other types of tests and prognostic models to help decide the most effective treatment options for someone. If your doctor suggests using one of these ways to help determine your treatment options, have them explain what it can tell you, as well as how accurate it’s likely to be.
For men with prostate cancer that is localized (not thought to have spread outside the prostate), a major issue is that it’s often hard to tell how quickly the cancer is likely to grow and spread. This can make it hard to decide if the cancer needs to be treated right away, as well as which types of treatment might be good options.
Some types of lab tests, known as genomic, molecular, or proteomic tests, can be used along with other information (such as the risk groups above) to help better predict how quickly a prostate cancer might grow or spread, and as a result, help decide what treatment options might be best and when they should be given. These tests look at which genes or proteins are active inside the prostate cancer cells. Examples of such tests include:
These tests continue to be studied to find more areas where they can be useful in prostate cancer risk and treatment decisions.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Klein EA. Prostate cancer: Risk stratification and choice of initial treatment. In Savarese DMF, ed. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Last updated May 7, 2021. Accessed August 30, 2021.
National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Prostate Cancer. Version 1.2022. Accessed at www.nccn.org/professionals/physician_gls/pdf/prostate.pdf on October 4, 2021.
Ross A, D’Amico AV, Freedland S. Molecular prognostic tests for prostate cancer. In Savarese DMF, ed. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Last updated July 2, 2021. Accessed October 4, 2021.
Last Revised: May 12, 2023
Donate now so we can continue to provide access to critical cancer information, resources, and support to improve lives of people with cancer and their families.